Norwegian Finans Holding ASA
Bank Norwegian AS rated BBB (stable outlook) by Standard & Poor`s, has mandated SpareBank 1 Markets and Swedbank to arrange an investor presentation on 9 March 2021 at 10.00 CET, where one or more senior preferred bond issues in NOK and/or SEK with tenors up to 4 year may follow. Bond issues with call options will be considered.
In conjunction with the potential bond issues, the company will consider buybacks of BANKN22 (ISIN: NO0010848583) maturing 29 September 2021 and BANKN23 (ISIN: NO0010848591) maturing 29 March 2022.
The potential issuance and buyback are part of Bank Norwegian's general funding and will cover MREL requirements. The contemplated issuance is subject to market conditions.
Contact persons:
CFO Klara-Lise Aasen; phone +47 47 63 55 83; kaa@banknorwegian.no
Head of treasury Mats Benserud; phone +47 95 89 15 39; mbe@banknorwegian.no
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
GDU-TECH CO., LTD.7.1.2026 01:00:00 CET | Press release
GDU Launches UAV-P300, The World’s First Drone with AI-Driven Optical & Electronic Fog Penetration Capabilities
CNH Industrial N.V.6.1.2026 23:00:00 CET | Press release
Pricing of CNH Industrial Capital LLC $500 million notes
Alvotech6.1.2026 21:00:00 CET | Press release
Transactions of Managers and Closely Associated Persons
Alvotech6.1.2026 21:00:00 CET | Press release
Transactions of Managers and Closely Associated Persons
Zymeworks Inc.6.1.2026 19:34:22 CET | Press release
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
